» Articles » PMID: 36977946

Diminished Vasculogenesis Under Inflammatory Conditions is Mediated by Activin A

Overview
Journal Angiogenesis
Publisher Springer
Specialty Hematology
Date 2023 Mar 28
PMID 36977946
Authors
Affiliations
Soon will be listed here.
Abstract

Severe inflammatory stress often leads to vessel rarefaction and fibrosis, resulting in limited tissue recovery. However, signaling pathways mediating these processes are not completely understood. Patients with ischemic and inflammatory conditions have increased systemic Activin A level, which frequently correlates with the severity of pathology. Yet, Activin A's contribution to disease progression, specifically to vascular homeostasis and remodeling, is not well defined. This study investigated vasculogenesis in an inflammatory environment with an emphasis on Activin A's role. Exposure of endothelial cells (EC) and perivascular cells (adipose stromal cells, ASC) to inflammatory stimuli (represented by blood mononuclear cells from healthy donors activated with lipopolysaccharide, aPBMC) dramatically decreased EC tubulogenesis or caused vessel rarefaction compared to control co-cultures, concurrent with increased Activin A secretion. Both EC and ASC upregulated Inhibin Ba mRNA and Activin A secretion in response to aPBMC or their secretome. We identified TNFα (in EC) and IL-1β (in EC and ASC) as the exclusive inflammatory factors, present in aPBMC secretome, responsible for induction of Activin A. Similar to ASC, brain and placental pericytes upregulated Activin A in response to aPBMC and IL-1β, but not TNFα. Both these cytokines individually diminished EC tubulogenesis. Blocking Activin A with neutralizing IgG mitigated detrimental effects of aPBMC or TNFα/IL-1β on tubulogenesis in vitro and vessel formation in vivo. This study delineates the signaling pathway through which inflammatory cells have a detrimental effect on vessel formation and homeostasis, and highlights the central role of Activin A in this process. Transitory interference with Activin A during early phases of inflammatory or ischemic insult, with neutralizing antibodies or scavengers, may benefit vasculature preservation and overall tissue recovery.

Citing Articles

In-silico analysis predicts disruption of normal angiogenesis as a causative factor in osteoporosis pathogenesis.

James R, Subramanyam K, Payva F, E A, Tv V, Sivaramakrishnan V BMC Genom Data. 2024; 25(1):85.

PMID: 39379846 PMC: 11460074. DOI: 10.1186/s12863-024-01269-z.


Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.

Souza R, Badesch D, Ghofrani H, Gibbs J, Gomberg-Maitland M, McLaughlin V Eur Respir J. 2023; 62(3).

PMID: 37696565 PMC: 10512088. DOI: 10.1183/13993003.01107-2023.

References
1.
Cuijpers I, Simmonds S, Van Bilsen M, Czarnowska E, Miqueo A, Heymans S . Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. Basic Res Cardiol. 2020; 115(4):39. PMC: 7248044. DOI: 10.1007/s00395-020-0798-y. View

2.
Goligorsky M . Microvascular rarefaction: the decline and fall of blood vessels. Organogenesis. 2010; 6(1):1-10. PMC: 2861737. DOI: 10.4161/org.6.1.10427. View

3.
Wong B, Marsch E, Treps L, Baes M, Carmeliet P . Endothelial cell metabolism in health and disease: impact of hypoxia. EMBO J. 2017; 36(15):2187-2203. PMC: 5538796. DOI: 10.15252/embj.201696150. View

4.
Singhal A, Symons J, Boudina S, Jaishy B, Shiu Y . Role of Endothelial Cells in Myocardial Ischemia-Reperfusion Injury. Vasc Dis Prev. 2015; 7:1-14. PMC: 4280830. DOI: 10.2174/1874120701007010001. View

5.
Basile D . Rarefaction of peritubular capillaries following ischemic acute renal failure: a potential factor predisposing to progressive nephropathy. Curr Opin Nephrol Hypertens. 2004; 13(1):1-7. DOI: 10.1097/00041552-200401000-00001. View